A bevy of transactions in the pharmaceutical industry and industrial sector in Europe helped make the past week a big one for M&A, with more than a dozen billion-dollar deals being announced.
Israel’s Teva Pharmaceutical Industries Ltd. turned to Sullivan & Cromwell to advise on its $40.5 billion acquisition of the generic drug business of Dublin-based Allergan, represented by Latham & Watkins. As noted by The Am Law Daily earlier this week, the deal effectively pulled the plug on Teva’s hostile bid for fellow generic drug maker Mylan NV, which had not fared well.
